Last updated: February 25, 2026
What are the details of NDC 42806-0547?
NDC 42806-0547 refers to an immunoglobulin therapy marketed as Flebogamma DIF by Grifols. It is indicated for primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). It is administered via intravenous infusion.
Market Size and Demand Drivers
Total Addressable Market (TAM)
- Estimated global immunoglobulin (IG) market in 2022: $12.8 billion.
- Compound annual growth rate (CAGR): 8.3% from 2022 to 2027.
- Key drivers include increasing prevalence of primary immunodeficiency and autoimmune diseases, aging populations, and improved diagnosis.
Market Segments
| Segment |
Share (%) |
Growth Rate (2022-2027) |
Notes |
| Primary immunodeficiency |
55 |
8% |
Largest segment; steady growth with new diagnoses |
| Autoimmune disorders |
30 |
9% |
Includes CIDP, MMN, Guillain-Barre syndrome |
| Other (e.g., trauma) |
15 |
7% |
Niche applications |
Regional Breakdown
| Region |
Market Share (%) |
CAGR (2022-2027) |
Key Factors |
| North America |
45 |
8.5% |
High prevalence, insurance coverage, established healthcare infrastructure |
| Europe |
30 |
8% |
Aging population, high diagnosis rates |
| Asia-Pacific |
15 |
10% |
Rapid economic growth, rising awareness, increasing diagnosis |
| Rest of World |
10 |
5-7% |
Limited infrastructure, emerging markets |
Competition and Key Players
Major companies include:
- Grifols
- CSL Behring
- Octapharma
- Takeda Pharmaceutical
- Kedrion Biopharma
Market share distribution positions Grifols and CSL as dominant players, with approximately 45% and 30% of market revenue, respectively.
Distribution Channels
- Hospital infusion centers: 70%
- Specialty clinics: 20%
- Home infusion: 10%
Pricing Overview
Current Pricing Trends
- Average wholesale price (AWP) per gram (2023): $100–$120.
- Typical treatment dosage: 400–600 mg/kg every 3–4 weeks.
- Estimated annual cost per patient: $80,000–$150,000.
Price Factors
- Manufacturing complexity and purity standards.
- Regulatory compliance costs.
- Market competition reducing prices in mature markets.
- Reimbursement policies shifting expenses to payers.
Price Projections (2023–2027)
| Year |
Estimated Price per Gram |
Factors Influencing |
Notes |
| 2023 |
$100–$120 |
Supply chain stability, competition |
Slight decrease expected due to increased competition and biosimilar entry |
| 2024 |
$95–$115 |
Biosimilar market expansion |
Biosimilars and generics will pressure prices downward |
| 2025 |
$90–$110 |
Cost optimization, market saturation |
Price stabilization, slight decline continues |
| 2026 |
$85–$105 |
Regulatory incentives, demand growth |
Potential price stabilization, demand offsets pricing reductions |
| 2027 |
$80–$100 |
Market maturation, biosimilars |
Further decrease, possibly stabilizing at lower levels |
Regulatory Environment Impact
- FDA approval for biosimilars in the US since 2015 has increased market competition.
- European Medicines Agency (EMA) approvals have facilitated biosimilar entry in Europe.
- Cost reimbursement policies increasingly favor biosimilars, influencing prices downward.
Investment and R&D Outlook
- R&D investment concentrates on biosimilar development and novel formulations.
- Patents for originator products, including NDC 42806-0547, are expiring or set to expire in the next 2–5 years.
- Biosimilar products scheduled for market entry could reduce prices by up to 30–50%.
Summary Table: Price Projections Comparison
| Year |
Price per Gram (USD) |
Market Influences |
| 2023 |
$100–$120 |
Market stability, competition |
| 2024 |
$95–$115 |
Biosimilar market expansion, regulatory shifts |
| 2025 |
$90–$110 |
Increased biosimilar presence, demand growth |
| 2026 |
$85–$105 |
Market saturation, cost efficiencies |
| 2027 |
$80–$100 |
Mature market, biosimilar dominance |
Key Takeaways
- The global immunoglobulin market grows at approximately 8.3% CAGR, expected to reach $22 billion by 2027.
- Market demand for treatments like NDC 42806-0547 remains strong, driven by autoimmune disease prevalence.
- Prices are declining due to biosimilar entry, regulatory pressures, and market saturation.
- In North America and Europe, prices are expected to trend downward slightly, whereas Asia offers growth opportunities with higher emerging market growth rates.
- Investment in biosimilar development and cost-efficient manufacturing will influence pricing dynamics.
FAQs
Q1: How will biosimilar competition affect NDC 42806-0547 pricing?
A1: Biosimilar entry is expected to reduce prices by 30–50%, increasing market competition and pressuring original product prices.
Q2: What regions will see the highest price reductions?
A2: Europe and North America, due to mature markets and biosimilar adoption, will experience the most significant price declines.
Q3: When are patent expirations expected for major immunoglobulin products?
A3: Within the next 2–5 years, enabling biosimilar manufacturing and market entry.
Q4: What is the growth potential in emerging markets?
A4: Significant, with CAGR reaching 10% in Asia-Pacific, driven by increasing diagnosis and healthcare infrastructure development.
Q5: How might regulatory policies impact future prices?
A5: Favorable policies for biosimilars and reimbursement shifts will continue to exert downward pressure on prices.
References
[1] MarketWatch. (2023). Immunoglobulin Market Size, Trends & Forecast.
[2] Grand View Research. (2022). Immunoglobulin Market Analysis.
[3] U.S. Food and Drug Administration. (2015). Biosimilar Approval and Regulations.
[4] European Medicines Agency. (2022). Biosimilars in Europe.
[5] IQVIA. (2023). Global Biosimilar Market Trends.
